Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.41 |
| ▸ | CPT1A | P50416 | 10/20 | 0.41 |
| ▸ | CPT2 | P23786 | 6/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166634 | 0.91 | ALDH1A1 (0.40) | CPT1AALDH1A1MAPK1 | |
| SCHEMBL17396055 | 0.88 | GCK (0.42) | CPT1AALDH1A1MAPK1 | |
| SCHEMBL6167867 | 0.85 | CPT1A (0.38) | DAGLACPT1ACPT2CPT1BP2RY12 | |
| SCHEMBL12600595 | 0.84 | TMEM97 (0.48) | DAGLACPT1ACPT2TMEM97SIGMAR1 | |
| SCHEMBL1061828 | 0.84 | TMEM97 (0.48) | DAGLACPT1ACPT2TMEM97SIGMAR1 | |
| SCHEMBL26989028 | 0.83 | NPC1 (0.46) | CPT1ACPT2PRCPALDH1A1MAPK1 | |
| SCHEMBL6166994 | 0.82 | KDM4E (0.46) | P2RY12ALDH1A1 | |
| SCHEMBL6167855 | 0.82 | CPT1A (0.43) | DAGLACPT1ACPT2CPT1BALDH1A1 | |
| SCHEMBL6167984 | 0.81 | P2RY12 (0.44) | P2RY12 | |
| SCHEMBL23247779 | 0.81 | CPT1A (0.46) | DAGLACPT1ACPT2PRCPCPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349850-B1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | SOD CONSEILS RECH APPLIC (FR) | 2005-09-07 | — | — | EP | claimed |
| US-20040077640-A1 | Sodium channel modulators derived from 2-piperidylimidazoles | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077640-A1 | Sodium channel modulators derived from 2-piperidylimidazoles | KCNH1, HCN4, KCNH2 | DAGLA 2629/4885CPT1A 3561/4885CPT2 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.